[1]郭晓鹏,王裕,马文斌.脑室播散型复发性胶质母细胞瘤放疗联合靶向治疗及免疫治疗后存活2.5年1例报道并文献复习[J].中国临床神经外科杂志,2024,29(12):720-723728.[doi:10.13798/j.issn.1009-153X.2024.12.004]
　GUO Xiao-peng,WANG Yu,MA Wen-bin.Radiotherapy combined with targeted therapy and immunotherapy for ventricular disseminated recurrent glioblastoma surviving for 2.5 years: a case report and literature review[J].,2024,29(12):720-723728.[doi:10.13798/j.issn.1009-153X.2024.12.004]
点击复制

脑室播散型复发性胶质母细胞瘤放疗联合靶向治疗及免疫治疗后存活2.5年1例报道并文献复习()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
29
期数:
2024年12期
页码:
720-723728
栏目:
论著
出版日期:
2024-12-30

文章信息/Info

Title:
Radiotherapy combined with targeted therapy and immunotherapy for ventricular disseminated recurrent glioblastoma surviving for 2.5 years: a case report and literature review
文章编号:
1009-153X（2024）12-0720-04
作者:
郭晓鹏; 王裕; 马文斌
100730北京，中国医学科学院北京协和医学院北京协和医院神经外科（郭晓鹏、王裕、马文斌）
Author(s):
GUO Xiao-peng;  WANG Yu;  MA Wen-bin
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
关键词:
胶质母细胞瘤; 脑室播散; 靶向治疗; 免疫治疗; 放射治疗
Keywords:
Glioblastoma;  Ventricular dissemination;  Targeted therapy;  Immunotherapy;  Radiotherapy
分类号:
R 739.41
DOI:
10.13798/j.issn.1009-153X.2024.12.004
文献标志码:
A
摘要:
目的 探讨脑室播散型复发性胶质母细胞瘤（GBM）的治疗方法及疗效。方法 回顾性分析1例脑室播散型复发性GBM的临床资料，并结合相关文献进行总结分析。结果 1例57岁男性，因右侧颞枕叶占位，行开颅手术全切除病变，术后病理显示IDH野生型GBM（WHO分级4级），MGMT启动子非甲基化；术后给予标准Stupp方案治疗。术后1年复查MRI发现左侧脑室壁近室间孔处及透明隔结节样强化，考虑疾病进展，进行化疗5 d，因并发严重免疫抑制合并重症肺炎而停止化疗；4个月后复查MRI发现左侧尾状核头、胼胝体膝、透明隔结节样强化灶显著增大，对新发病灶行三维调强放疗；1个月复查MRI显示病变继续进展，双侧脑室及第四脑室软膜强化，考虑脑室播散。采用帕博利珠PD-1单抗和贝伐珠单抗治疗2个疗程，病灶完全消失。2年后，病人自行停用单抗治疗。停用半年复查MRI发现左侧脑室内广泛病灶，继续采用单抗治疗，但病变仍快速进展；1个月后复查MRI显示左侧侧脑室及第四脑室被强化的病灶完全填充，2个月后，病人死亡。结论 本文病例总生存期超过4年，自脑室播散后总生存期维持约2.5年。这提示放疗+靶向+免疫的联合治疗方案可能成为复发性GBM病人的可选治疗方案之一。
Abstract:
Objective To explore the treatment methods and efficacy of ventricular disseminated recurrent glioblastoma multiforme (GBM). Methods A retrospective analysis was conducted on the clinical data of a patient with ventricular disseminated recurrent GBM, and the relevant literature was summarized and analyzed. Results The patient was a 57-year-old male who underwent craniotomy for total resection of a right temporal-parietal lobe mass. The postoperative pathology showed IDH wild-type GBM (WHO grade 4) with unmethylated MGMT promoter. The patient received standard Stupp protocol treatment after surgery. One year after surgery, MRI showed nodular enhancement near the interventricular foramen and septum pellucidum on the left ventricular wall, suggesting disease progression. Five days of chemotherapy was administered, but it was stopped due to severe immunosuppression and severe pneumonia. Four months later, MRI showed significant enlargement of nodular enhancement in the left caudate nucleus, genu of the corpus callosum, and septum pellucidum. Three-dimensional intensity-modulated radiotherapy was performed on the new lesions. One month later, MRI showed continued disease progression with soft meningeal enhancement in both lateral ventricles and the fourth ventricle, indicating ventricular dissemination. Subsequently, two courses of combined treatment with pembrolizumab (PD-1 inhibitor) and bevacizumab were administered, and the lesions completely disappeared. Two years later, the patient stopped the monoclonal antibody treatment on his own. Six months after drug withdrawal, MRI showed extensive lesions in the left ventricle. Monoclonal antibody treatment was resumed, but the lesions still progressed rapidly. One month later, MRI showed that the left lateral ventricle and the fourth ventricle were completely filled with enhanced lesions. The patient died two months later. Conclusion The total survival period of this case exceeded 4 years, and the survival period after ventricular dissemination was approximately 2.5 years. This suggests that radiotherapy combined with targeted therapy and immunotherapy may be a potential treatment option for patients with recurrent GBM.

参考文献/References:

[1] STUPP R, MASON WP, VAN DEN BENT MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma [J]. N Engl J Med, 2005, 352(10): 987-996.
[2] STUPP R, TAILLIBERT S, KANNER A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial [J]. JAMA, 2017, 318(23): 2306-2316.
[3] CHEN F, WENDL MC, WYCZALKOWSKI MA, et al. Moving pancancer studies from basic research toward the clinic [J]. Nat Cancer, 2021, 2(9): 879-890.
[4] WICK W, GORLIA T, BENDSZUS M, et al. Lomustine and bevacizumab in progressive glioblastoma [J]. N Engl J Med, 2017, 377 (20): 1954-1963.
[5] SAHEBJAM S, FORSYTH PA, TRAN ND, et al. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study [J]. Neuro Oncol, 2021, 23(4): 677-686.
[6] GUO X, WANG S, WANG Y, et al. Anti-PD-1 plus anti-VEGF therapy in multiple intracranial metastases of a hypermutated, IDH wild-type glioblastoma [J]. Neuro Oncol, 2021, 23(4): 699-701.
[7] LEONE A, COLAMARIA A, FOCHI NP, et al. Recurrent glioblastoma treatment: state of the art and future perspectives in the precision medicine era [J]. Biomedicines, 2022, 10(8): 1927.
[8] WEN PY, MACDONALD DR, REARDON DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group [J]. J Clin Oncol, 2010, 28(11): 1963-1972.
[9] OKADA H, WELLER M, HUANG R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group [J]. Lancet Oncol, 2015, 16(15): e534-e542.
[10] REARDON DA, BRANDES AA, OMURO A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial [J]. JAMA Oncol, 2020, 6(7): 1003-1010.
[11] BOUFFET E, LAROUCHE V, CAMPBELL BB, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency [J]. J Clin Oncol, 2016, 34(19): 2206-2211.
[12] ERSON-OMAY EZ, CAGLAYAN AO, SCHULTZ N, et al. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis [J]. Neuro Oncol, 2015, 17(10):1356-1364.
[13] JOHANNS TM, MILLER CA, DORWARD IG, et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy [J]. Cancer Discov, 2016, 6(11): 1230-1236.
[14] OKITA Y, NONAKA M, UMEHARA T, et al. Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: a case report [J]. Oncol Lett, 2015, 9(4): 1885-1888.
[15] HEGI ME, DISERENS AC, GORLIA T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma [J]. N Engl J Med, 2005, 352(10): 997-1003.

相似文献/References:

[1]谢宝树　张　林　王　宇　贾　锋　殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
　XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(12):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]宋贵东 综述　高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]
[3]李继强　杨吉安　邵灵敏　吴庭枫　刘宝辉　陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
　LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(12):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[4]桂志勇　冯　军　黄俊红　白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
　GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[5]王娇燕　孟凡华　刘魏然　魏春晓　林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
　WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(12):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[6]张治元　王汉东　樊友武　贾　玥　吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
　ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(12):69.
[7]郑锐哲　姜秀峰　陈二涛　孙兆良　冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[8]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
　HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(12):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[9]殷安安　陆　南　贺亚龙　章　翔　刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
　YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(12):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
[10]吴　蛟　易　勇　赵卓琳　周良学　周世军.贝伐珠单抗联合化疗治疗胶质母细胞瘤的meta分析[J].中国临床神经外科杂志,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]
　WU Jiao,YI Yong,ZHAO Zhuo-lin,et al.Efficacy and safety of bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis[J].,2020,(12):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]

备注/Memo

备注/Memo:
（2023-07-02收稿，2024-04-02修回）
通信作者：王　裕，Email：ywang@pumch.cn
更新日期/Last Update: 2024-12-30